MedTrace Logo

Treatment of Cerebral Arteriovenous Malformations With SQUID Liquid Embolic Agent (CHOICE)

NCT03413852 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 111

Last updated 2021-04-30

No results posted yet for this study

Summary

The objective of this study is to further establish that SQUID, an alternative liquid embolic agent with specific properties, is a safe and effective alternative in bAVM endovascular treatment strategy available to date. Therefore, the performance of SQUID will be documented and its safety of use will be confirmed in current practice.

Conditions

  • Cerebral Arteriovenous Malformation

Interventions

DEVICE

SQUID non-adhesive liquid embolic agent

AVM embolization using SQUID non-adhesive liquid embolic agent

Sponsors & Collaborators

  • Embo-Flüssigkeiten A.G.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-11
Primary Completion
2022-03-31
Completion
2022-08-31

Countries

  • Belgium
  • Denmark
  • France
  • Germany
  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03413852 on ClinicalTrials.gov